JP2021502392A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502392A5
JP2021502392A5 JP2020526149A JP2020526149A JP2021502392A5 JP 2021502392 A5 JP2021502392 A5 JP 2021502392A5 JP 2020526149 A JP2020526149 A JP 2020526149A JP 2020526149 A JP2020526149 A JP 2020526149A JP 2021502392 A5 JP2021502392 A5 JP 2021502392A5
Authority
JP
Japan
Prior art keywords
ataxia
medicament according
patient
administered
riluzole prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020526149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502392A (ja
JP7352542B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/060232 external-priority patent/WO2019094851A1/en
Publication of JP2021502392A publication Critical patent/JP2021502392A/ja
Publication of JP2021502392A5 publication Critical patent/JP2021502392A5/ja
Priority to JP2023149803A priority Critical patent/JP2023175823A/ja
Application granted granted Critical
Publication of JP7352542B2 publication Critical patent/JP7352542B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020526149A 2017-11-12 2018-11-11 運動失調を処置するためのリルゾールプロドラッグの使用 Active JP7352542B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023149803A JP2023175823A (ja) 2017-11-12 2023-09-15 運動失調を処置するためのリルゾールプロドラッグの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US62/584,856 2017-11-12
US201862717948P 2018-08-13 2018-08-13
US62/717,948 2018-08-13
PCT/US2018/060232 WO2019094851A1 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023149803A Division JP2023175823A (ja) 2017-11-12 2023-09-15 運動失調を処置するためのリルゾールプロドラッグの使用

Publications (3)

Publication Number Publication Date
JP2021502392A JP2021502392A (ja) 2021-01-28
JP2021502392A5 true JP2021502392A5 (cg-RX-API-DMAC7.html) 2021-10-21
JP7352542B2 JP7352542B2 (ja) 2023-09-28

Family

ID=66438598

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526149A Active JP7352542B2 (ja) 2017-11-12 2018-11-11 運動失調を処置するためのリルゾールプロドラッグの使用
JP2023149803A Pending JP2023175823A (ja) 2017-11-12 2023-09-15 運動失調を処置するためのリルゾールプロドラッグの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023149803A Pending JP2023175823A (ja) 2017-11-12 2023-09-15 運動失調を処置するためのリルゾールプロドラッグの使用

Country Status (26)

Country Link
US (3) US20210023061A1 (cg-RX-API-DMAC7.html)
EP (4) EP4696324A3 (cg-RX-API-DMAC7.html)
JP (2) JP7352542B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200103658A (cg-RX-API-DMAC7.html)
CN (1) CN112292127A (cg-RX-API-DMAC7.html)
AU (1) AU2018364749C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020009173A2 (cg-RX-API-DMAC7.html)
CA (1) CA3082096A1 (cg-RX-API-DMAC7.html)
DK (2) DK3706739T3 (cg-RX-API-DMAC7.html)
ES (1) ES2996892T3 (cg-RX-API-DMAC7.html)
FI (2) FI3706739T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241675T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070302T2 (cg-RX-API-DMAC7.html)
IL (1) IL274532B2 (cg-RX-API-DMAC7.html)
LT (2) LT3706739T (cg-RX-API-DMAC7.html)
MD (2) MD3706739T2 (cg-RX-API-DMAC7.html)
MX (2) MX2020004678A (cg-RX-API-DMAC7.html)
PH (1) PH12020550583A1 (cg-RX-API-DMAC7.html)
PL (2) PL3706739T3 (cg-RX-API-DMAC7.html)
PT (2) PT3706739T (cg-RX-API-DMAC7.html)
RS (2) RS67956B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202004332XA (cg-RX-API-DMAC7.html)
SI (2) SI3706739T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202500022T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019094851A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002626B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
DK3265448T3 (da) 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
EP4426702A1 (en) * 2021-11-04 2024-09-11 Skyhawk Therapeutics, Inc. Condensed-pyrazine amine derivatives for treating sca3
JP2025517509A (ja) * 2022-05-23 2025-06-05 バイオヘイブン・セラピューティクス・リミテッド 脊髄小脳失調症を治療する方法
WO2026078657A1 (en) 2024-10-10 2026-04-16 Biohaven Therapeutics Ltd. Prodrugs of riluzole

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
ES2318869T3 (es) 1997-02-20 2009-05-01 Massachusetts Institute Of Technology Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion.
DK1001748T3 (da) 1997-07-25 2006-08-21 Alpex Pharma Sa Fremgangsmåde til fremstilling af et granulat, som er egnet til fremstilling af i munden oplöselige tabletter, som kan sönderdeles hurtigt
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
JP2005508939A (ja) 2001-10-12 2005-04-07 エラン ファーマ インターナショナル,リミティド 即時放出および徐放特性を組み合わせて有する組成物
WO2003068604A1 (en) 2002-02-13 2003-08-21 Weibel Michael K Drug dose-form and method of manufacture
ATE337003T1 (de) * 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
CN101686942B (zh) 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
EP2271344A4 (en) * 2008-03-31 2011-04-27 Univ South Florida METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8545806B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf

Similar Documents

Publication Publication Date Title
Roberts Onychomycosis: current treatment and future challenges
CN108721265B (zh) 通过给予秋水仙碱衍生物治疗或预防心血管事件
JP2015524444A5 (cg-RX-API-DMAC7.html)
JP2020534362A (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
MX2014006547A (es) Tratamiento combinado del cancer.
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
US20100093754A1 (en) Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
CN116712422A (zh) 治疗特定患者群体的神经变性病症的方法
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および/または神経精神医学的障害を改善するための4−アミノピリジンの使用
JP2022533968A5 (cg-RX-API-DMAC7.html)
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2021530543A5 (cg-RX-API-DMAC7.html)
CA2313270A1 (en) Use of deferiprone in treating and preventing iron-induced cardiac disease
JP2019507786A5 (cg-RX-API-DMAC7.html)
JP2021512086A5 (cg-RX-API-DMAC7.html)
ES2275619T3 (es) Quetiapina para el tratamiento de discinesia en pacientes no psicoticos.
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
ES2668943T3 (es) Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz
CN106507666A9 (zh) 1,3‑丙二磺酸或其药学上可接受的盐用于治疗肉样瘤病的用途
JP2022525679A (ja) 境界性パーソナリティ障害の処置方法
JP6420923B1 (ja) 医薬
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
JP2024541770A5 (cg-RX-API-DMAC7.html)